Allergies, Author Interviews, Duke / 25.06.2024

MedicalResearch.com Interview with: Professor Soman Abraham PhD Grace Kerby Distinguished Professor of Pathology Duke University. Dr. Abraham led the research when working in the Emerging Infectious Diseases Research Programme at Duke-NUS Medical School in Singapore MedicalResearch.com: What is the background for this study? Response: The degranulation of mast cells (MCs) is a process that leads to allergic symptoms, ranging from itching, redness, and swelling of the tissue to severe and potentially life-threatening anaphylaxis involving multiple organ systems. According to the World Health Organization (WHO), more than 10 per cent of the global population suffers from food allergies. As allergy rates continue to rise, so does the incidence of food-triggered anaphylaxis and asthma worldwide. In view of the fact that allergic diseases are difficult to prevent or treat, we sought to understand the underlying basis for anaphylactic reactions. (more…)
Allergies, Exercise - Fitness / 06.06.2024

Understanding the Impact of Allergies on WorkoutsImagine gearing up for a workout, only to be hit with a sudden wave of sneezing or a stuffy nose. It's frustrating and can easily derail your fitness plans. Allergies can make even the most dedicated fitness enthusiasts want to give up. This scenario is all too common, especially during allergy season when pollen counts are high, and allergens are everywhere. The impact of allergies on workouts can be discouraging, but it doesn’t have to stop you from achieving your fitness goals. If this sounds like your experience, you’re not alone. Many people find their exercise routines interrupted by allergies. This article offers practical tips to help you stay motivated and manage your allergies during workouts. 1. Understanding the Impact of Allergies on Workouts Allergies can have a big impact on your physical performance. Symptoms like sneezing, congestion, itchy eyes, and fatigue can make it challenging to stick to your exercise routine. These symptoms can lower your stamina, make breathing harder, and reduce your overall workout intensity. Managing allergies effectively is key to maintaining a consistent fitness regimen and achieving your health goals. (more…)
Allergies / 16.05.2024

Allergy drops, not to be confused with allergy eye drops, have been gaining popularity for their convenient and effective approach to tackling pesky allergies. But are allergy drops the same as allergy immunotherapy? This option falls under the umbrella of allergy immunotherapy, and while allergy drops are allergy immunotherapy, not all allergy immunotherapy are allergy drops.  In this blog, we’ll explore allergy immunotherapy and allergy drops to help you better understand the best course of action for combatting your pesky allergies. 

Understanding Allergy Immunotherapy

Allergy immunotherapy (AIT) is a treatment that desensitizes the body to an allergen. It’s much unlike traditional allergy treatments, such as corticosteroids, decongestants, and antihistamines, because it focuses on the allergy, not the symptoms.  To understand how it works, we need to understand what an allergy is. Simply put, an allergy is a reaction in the body to a foreign substance called an allergen, such as bee venom or pet dander. When your body comes into contact with the allergen, your antibodies send a signal to specific cells that release chemicals, resulting in an allergic reaction.  allergies-allergy-pexelsThe reaction triggers the symptoms you recognize as your allergy, such as a runny nose and itchy eyes.  To desensitize your body to the allergen and help your body become less reactive, allergy immunotherapy delivers a small dose of the allergen under your skin or tongue. This small, incrementally increasing dose helps your body adjust, “training” it to become less sensitive.  It achieves this result by minimizing the production of “blocking” antibodies responsible for the reaction. Over time and with consistent doses, you may find that you can be exposed to the allergen with little to no reaction.  However, it’s important to note that everybody is different. Most people notice some results within the first year, but the most noticeable results usually take two to three years after beginning treatment.  (more…)
Allergies, Author Interviews, Dermatology, University of Michigan / 16.11.2023

MedicalResearch.com Interview with: Charles Schuler, MD Assistant Professor Allergy and Clinical Immunology & Mary H. Weiser Food Allergy Center University of Michigan MedicalResearch.com: What is the background for this study? Response: Anaphylaxis is a severe allergic reaction that may include a skin rash, nausea, vomiting, difficulty breathing, and shock. Food anaphylaxis sends 200,000 people to the emergency room annually in the United States. Oral food challenges are when a patient ingests increasing doses up to a full serving of the suspected food allergen under supervision of a medical provider, usually an allergist. These oral food challenges are the diagnostic standard for food allergy/anaphylaxis as skin and blood allergy tests have high false positive rates. Although a highly accurate test, patients often experience anaphylaxis during oral food challenges necessitating an epinephrine injection. (more…)
Allergies, Author Interviews, CDC, Environmental Risks / 04.08.2023

MedicalResearch.com Interview with: Ann Carpenter DVM, MPH Epidemic Intelligence Service Officer Centers for Disease Control and Prevention Primary author of the recent CDC MMWR report.  MedicalResearch.com: What is the background for this study? Would you briefly describe Alpha-gal Syndrome?  Response: Alpha-gal syndrome is an emerging and potentially life-threatening allergic condition that is associated with a tick bite. It is also called alpha-gal allergy, red meat allergy, or tick bite meat allergy. Increasing case studies and anecdotal reports suggested that AGS was a growing concern, but, prior to these studies, information on clinician awareness and the number of people impacted was not available at a national level. (more…)
Allergies, Author Interviews, Pediatrics / 10.05.2023

MedicalResearch.com Interview with: Matthew Greenhawt, MD, MBA, MSc Professor of Pediatrics Section of Allergy and Immunology Director, Food Challenge and Research Unit Children’s Hospital Colorado University of Colorado School of Medicine Anschutz Medical Campus Aurora, CO 80045   MedicalResearch.com: What is the background for this study? Is the incidence of peanut allergy in toddlers stabilizing with the earlier introduction of peanuts? Response: There exists an urgent unmet medical need for infants and toddlers living with peanut allergy. Peanut allergy affects approximately 2% of U.S. children and has been a growing public health problem over the past 20 years. In fact, the number of kids affected by peanut allergy has tripled in that time span. Peanut allergy is not likely to be naturally outgrown, and reactions can be severe. However, there is hope. There is growing evidence that the allergic immune system is more modifiable early in life. The EPITOPE study evaluated Viaskin Peanut in children ages 1 – 3 years of age. Viaskin Peanut is an investigational epicutaneous immunotherapy (EPIT) product, which uses the skin as a route to desensitize a patient to be less reactive to peanut. This is a daily therapy, worn between the shoulders on the back, which allows for non-oral peanut desensitization, which many parents find highly appealing. (more…)
Allergies, Author Interviews, Cancer Research, Dermatology, Melanoma / 17.03.2023

MedicalResearch.com Interview with: Jenni Komulainen University of Eastern Finland | UEF MedicalResearch.com: What is the background for this study? Response: The background for this study comes from the earlier findings that the skin cancer risk and atopic status have some connection, but the results have been inconsistent. The connection between atopy and skin cancers may be related to the stimulation of protective immune response or the predisposition to carcinogenesis through chronic inflammation. The aim of this study was to investigate if atopic disorders associate with skin cancers. (more…)
Allergies, Author Interviews, Dermatology / 09.03.2023

MedicalResearch.com Interview with: Nicholas Gulati, MD, PhD Director, Early Detection of Skin Cancer and Oncodermatology Clinic The Kimberly and Eric J. Waldman Department of Dermatology Mount Sinai Health System New York, New York MedicalResearch.com: What is the background for this study? What is dupilumab primarily used for? Response: Dupilumab is a monoclonal antibody that inhibits a specific part of the immune system known as Th2 cells, which are important in the development of various diseases including atopic dermatitis (eczema) and asthma. Therefore, dupilumab has become one of the major treatments for these conditions. Given the increasing use of this drug, it is important to understand the safety of it in terms of cancer development, as that is currently largely unknown. (more…)
Allergies, Author Interviews, BMJ, Immunotherapy, Pediatrics / 13.01.2023

MedicalResearch.com Interview with: A/Prof Luke GrzeskowiakPhD | BPharm(Hons) | GCertClinEpid | AdvPracPharm | FSHP Associate Professor (Practitioner Fellow) Channel 7 Children’s Research Foundation Fellow in Medicines Use and Safety College of Medicine & Public Health Flinders University Affiliate Research Fellow – South Australian Health & Medical Research Institute (SAHMRI) Specialist Pharmacist – Flinders Women & Children, Flinders Medical Centre Adjunct Research Fellow – Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Adjunct Research Fellow – Robinson Research Institute, The University of Adelaide  MedicalResearch.com: What is the background for this study? Response: Peanut allergy affects 1-3% of children in Western countries, making it the most common food-related allergen. Only a small percentage (20%) of children grow out of their peanut allergy, with allergen avoidance and provision of rescue medications for the management of allergic reactions being the recognised mainstay of treatment for many years. However, avoidance of peanuts provides many challenges for children and their caregivers and requires children and caregivers to be hypervigilant regarding peanut ingestion, creating a significant burden. This burden can have a real impact on quality of life for children and their families. In more recent years there has been emerging interest in what is referred to as oral immunotherapy as an active preventive treatment to reduce the risk of accidental peanut exposure. Oral immunotherapy involves exposing children to an extremely small dose of peanut, typically in the form of peanut flour, and then gradually increasing that dose over time to build tolerance. We have been looking at opportunities for making oral immunotherapy safer, which would then make it more suitable for more people. Our previous research showed that boiling peanuts alters its protein structure and allergic properties, meaning they were less likely to cause a severe allergic reaction, but were still able to improve tolerance to peanut allergens. (more…)
Allergies, Author Interviews, JAMA, Pediatrics / 06.07.2022

MedicalResearch.com Interview with: Victoria Soriano PhD Research Assistant/Officer, Population Allergy University of Melbourne   MedicalResearch.com:  What is the background for this study?  Response: Peanut allergy is one of the most common childhood food allergies, and children rarely grow out of it. The only proven way to prevent peanut allergy is to give infants age-appropriate peanut products in the first year of life. We previously showed there was a dramatic increase in peanut introduction from 2007-11 to 2018-19, following changes to infant feeding guidelines. We wanted to know if earlier peanut introduction would reduce peanut allergy in the general population (in Melbourne, Australia). (more…)
Allergies, Annals Internal Medicine, Author Interviews, Pharmacology / 29.03.2022

MedicalResearch.com Interview with: Chintan V. Dave, PharmD, PhD Assistant Professor Ernest Mario School of Pharmacy Institute for Health, Health Care Policy and Aging Institute Rutgers University MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: The risks of anaphylaxis among intravenous (IV) iron products currently in use has not been assessed. Older adults have a higher risk of experiencing drug-induced anaphylaxis. Accordingly, our study objective was to elucidate the risk of anaphylaxis  among older adults receiving the five frequently used IV iron products: ferric carboxymaltose, ferumoxytol, ferric gluconate, iron dextran, and iron sucrose. (more…)
Allergies, Author Interviews / 26.02.2022

MedicalResearch.com Interview with: Edmond S. Chan MD, FRCPC, FCSACI, FAAAAI Head | Division of Allergy & Immunology | Department of Pediatrics, Faculty of Medicine Clinical Professor, The University of British Columbia Clinical Investigator, BC Children's Hospital Research Institute BC Children's Hospital, Allergy Clinic Vancouver, BC  Canada Treasurer, CSACI (Canadian Society of Allergy & Clinical Immunology) MedicalResearch.com:  What prompted you to look at the safety of peanut oral immunotherapy specifically in this patient population? Response: Our previous research has investigated the overall safety of peanut oral immunotherapy (OIT) in preschool populations. However, we have not investigated the relationship between specific patient characteristics and the safety of OIT. Previous literature has shown that patient factors, such as age, gender, baseline sIgE levels, and atopic comorbidities have been shown to impact the safety of OIT for other food allergies and in older patients. However, no data exist on which factors predict safety of peanut OIT in preschool populations. (more…)
Allergies, Author Interviews, COVID -19 Coronavirus, Dermatology, UCSF / 27.11.2021

MedicalResearch.com Interview with: Carina M. Woodruff, MD Department of Dermatolog University of California, San Francisco MedicalResearch.com: What is the background for this study? What are the main findings? Response: Rigorous hand hygiene has been an important component of the CDC's COVID-19 guidelines. With millions of Americans now using hand sanitizers regularly, we are seeing many more cases of hand dermatitis. Our study evaluated the key product features and most common allergens in the top-reviewed, commercial hand sanitizers sold by major US retailers. We found that the most common potential allergens were tocopherol, fragrance, propylene glycol and phenoxyethanol. Our study also showed that nearly 1 in 5 marketing claims on these products was misleading. For example, 70% of sanitizers with the marketing claim "hypoallergenic" included at least one common allergen in its formulation. (more…)
Allergies, Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies, Vanderbilt / 27.07.2021

MedicalResearch.com Interview with: Kimberly G. Blumenthal, MD, MSc Massachusetts General Hospital The Mongan Institute Boston, MA 02114 Matthew S. Krantz, MD Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: During the initial COVID-19 vaccine campaign with healthcare workers in December 2020, there was an unexpected higher than anticipated rate of immediate allergic reactions after Pfizer and Moderna mRNA vaccines.  This prompted both patient and provider concerns, particularly in those with underlying allergic histories, on the associated risks for immediate allergic reactions with the mRNA vaccines. Because of the significantly improved effectiveness of two doses of an mRNA vaccine compared to one dose, it was important to determine if those who experienced immediate allergic reaction symptoms after their first dose could go on to tolerate a second dose safely.    (more…)
Allergies, Author Interviews / 24.02.2021

MedicalResearch.com Interview with:  Authors: Mike Kulis, Johanna Smeekens, Edwin Kim, Vladimir Zarnitsyn, Samirkumar Patel MedicalResearch.com: What is the background for this study? Response: Peanut allergy is an IgE-mediated disease affecting approximately 2% of young children in the United States. Over the past decade, various forms of immunotherapy have been investigated with the goal of repeated daily allergen exposure leading to a desensitized state. One of these therapies, oral immunotherapy, or OIT, received FDA approval for treating peanut allergy in January 2020 with Aimmune’s Palforzia drug. While OIT effectively induces desensitization in a majority of patients, there is a substantial burden related to side effects, with an ever-present risk of systemic anaphylaxis. (more…)
Allergies, Author Interviews, Immunotherapy / 11.02.2021

MedicalResearch.com Interview with: Dr. Cathy Leonard PhD Department of Infection and Immunity Luxembourg Institute of Health Luxembourg MedicalResearch.com: What is the background for this study? Response: Cat allergy is a rapidly increasing phenomenon characterized by hypersensitivity and an excessive immune response to certain allergens associated with cats, among which the major allergen Fel d 1, a protein typically found in their saliva, on their skin and fur. Cat allergy manifestations can range from mild forms like itchy nose or sneezing to the development of severe symptoms such as rhinitis and asthma, with potentially fatal outcomes. Only Allergen‐specific immunotherapy (AIT )can ensure an effective and longer lasting treatment in the more advanced cases. AIT typically consists in the subcutaneous injection of gradually increasing doses of the allergen of interest, until a critical quantity is reached that induces long-term immune tolerance. Nevertheless, there is still the need to improve cat AIT in terms of efficacy and safety. We hypothesized that immune tolerance to the allergen could be boosted by improving the adjuvanticity of AIT solutions, thereby optimizing the production of antibodies against Fel d 1, while minimizing inflammation.  (more…)
Allergies, Author Interviews, Dermatology / 14.01.2021

MedicalResearch.com Interview with: Karan Lal, DO, Marketing Committee Member for the Society for Pediatric Dermatology, Dermatologist at UMass Memorial Medical Center. Dr. Lal discusses the recent study of a procedure to remove black dye from henna tattoos. MedicalResearch.com: What is the background for this study? Response: Para‐phenylenediamine, a dye frequently added to henna tattoos to create the black color, is a potent contact allergen. Severe contact dermatitis may arise within days even after the first application. Our objective was to develop a method for rapid and complete removal of para‐phenylenediamine‐containing black henna tattoos from the skin, an important problem many physicians are confronted with, but for which no simple method exists.  (more…)
Allergies, Author Interviews, OBGYNE, Pediatrics / 22.12.2020

MedicalResearch.com Interview with: Mia Stråvik PhD-student | Doktorand Department of Biology and Biological Engineering Division of Food and Nutrition Science Chalmers University of Technology MedicalResearch.com: What is the background for this study? Response: There is a need of research investigating the role of maternal diet during pregnancy and lactation on the baby’s allergy risk. Allergy is one of the most common chronic diseases of childhood, causing great suffering for the allergic child but also the entire family. Yet, the possibilities to cure and prevent this, in many cases life long, suffering are very limited. Previous research have indicated that maternal diet during pregnancy and lactation may affect the propensity of the child to develop an allergy, and diet is a factor you as a parent really can influence. (more…)
Allergies, Author Interviews, Dermatology / 06.12.2020

MedicalResearch.com Interview with: Jonathan Silverberg, MD, PHD, MPH Associate Professor Director of Clinical Research Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, DC MedicalResearch.com: What is the background for this study Response: Chronic hand eczema was previously shown to be associated with higher rates of allergic contact dermatitis. Yet, little is known about recent trends in North America with respect to the clinical presentation and allergen profile in chronic hand eczema. This study sought to determine the clinical characteristics and etiologies of hand eczema in a large North American cohort of adults referred for patch testing. The patients in the study were patch tested using the North American Contact Dermatitis Group’s allergen screening series. (more…)
Allergies, Author Interviews, Immunotherapy, Pediatrics / 04.12.2020

MedicalResearch.com Interview with: Lianne Soller, PhD Allergy Research Manager BC Children’s Hospital Allergy Clinic Vancouver, BC, Canada MedicalResearch.com: What is the background for this study? Response: Peanut oral immunotherapy (also known as OIT) has been studied for many years in clinical trials and has been found to be safe and effective in preschoolers. However, we know that clinical trials do not always reflect what happens in the real world. We wanted to see study whether peanut OIT would work as well in the real world. This is a follow up of our preschool peanut OIT safety study published in April 2019 which noted only 0.4% severe reactions and 4% epinephrine use during build-up. (more…)
Allergies, Author Interviews, Dermatology / 17.11.2020

MedicalResearch.com Interview with: Yashu Dhamija MD Dr. Thomas Schmidlin, MD Cleveland Clinic Akron General  MedicalResearch.com: What is the background for this study? Response: We are seeing an increased use of face masks in the COVID-19 pandemic and while that is encouraged and necessary to limit the spread of disease in the general publication, it can mean challenges for some individuals. Patients with known sensitizations to allergens contained in face masks may experience rash or irritation with commonly used face coverings. It is also possible for patients without a history of contact dermatitis to become sensitized to allergens after wearing facial coverings more regularly, thus leading to new cases of contact dermatitis (CD) in individuals with no known prior history of contact dermatitis. (more…)
Allergies, Author Interviews, ENT / 07.10.2020

MedicalResearch.com Interview with: Brent A. Senior, MD, FACS, FARS Professor of Otolaryngology/Neurosurgery Vice Chairman for Clinical Affairs Nathaniel and Sheila Harris Distinguished Professor Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery Department of Otolaryngology-Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill, NC MedicalResearch.com: What is the background for this study? How common is the problem of chronic rhinosinusitis with nasal polyps? Response: Chronic rhinosinusitis (CRS) is a very common illness in the United States and around the world, estimated to impact 2-14% of the US population. Chronic rhinosinusitis with polyps is a particularly challenging form of the disease marked by significant impact on quality of life, and being challenging to treat with significant recurrences of symptoms despite standard medical and surgical treatment. Inhaled intranasal steroids are standard therapy for patients with CRS including those with nasal polyps. However, many patients continue to have significant nasal symptoms despite treatment with these medications. This study was designed to answer the question of whether patients who had been receiving treatment with inhaled intranasal steroids and failed were improved by using EDS-FLU. Results were obtained by pooling data from two previous studies of the use of EDS-FLU in patients with CRS, called Navigate 1 and 2.   (more…)
Allergies, Author Interviews, CMAJ, Pediatrics / 23.09.2020

MedicalResearch.com Interview with: Melanie Leung, M.D.,C.M. candidate 2021 4th-year medical student at McGill University Division of Allergy and Clinical Immunology Department of Pediatrics, Montreal Children’s Hospital McGill University Health Centre, Montreal, QC, Canada Dr. Moshe Ben-Shoshan, MD, MSc Pediatric allergist and immunologist at the MCH (Montreal Children’s Hospital) and Scientist at the Research Institute of the MUHC (McGill University Health Center)   MedicalResearch.com: What is the background for this study? Response: In Canada, up to 9% of children have at least 1 food allergy. Anaphylaxis is the most severe and potential life-threatening manifestation of food allergy. Peanuts and tree nuts are the main culprits in food-induced anaphylaxis and account for most fatal cases in North America. Public awareness about peanut and nut anaphylaxis can help to prevent and to act promptly, in the case of anaphylactic reaction. However, the best timing for public awareness campaigns remained unknown, as no previous study looked at the potential association between specific times of the year, such as public holidays, and the incidence of peanut and tree nut anaphylaxis. Our aim was to evaluate the risk of peanut and tree nut-induced anaphylaxis on Halloween, Christmas, Easter, Diwali, Chinese New Year, and Eid al-Adha. Data was collected from 1390 pediatric cases of peanut or nut-induced anaphylaxis across Canada (Newfoundland & Labrador, Quebec, Ontario, and British  Columbia), from 2011 to 2020. 62% of children were boys and the median age was 5.4 years. We compared the average daily number of cases during each holiday and compared it to the rest of the year (i.e.: non-holiday period). (more…)
Allergies, Author Interviews, Genetic Research, Hepatitis - Liver Disease / 08.09.2020

MedicalResearch.com Interview with: Takanori Takebe MD Director for Commercial Innovation, Center for Stem Cell and Organoid Research and Medicine (CuSTOM) Assistant Professor, University Cincinnati Department of Pediatrics, Cincinnati Children’s Professor, Institute of Research Tokyo Medical and Dental University, Japan  MedicalResearch.com: What is the background for this study?  What are the main findings? Response: Drug induced liver injury (DILI) is rare yet highly unpredictable disorder that oftentimes causes drug failure withdrawn from the market during clinical trial even at a very rare incidence of DILI (1/10,000). Indeed, one particular drug TAK875 (Fasigliam) was the case despite promising efficacy. This not only disappoints patient but impact significant financial risk to pharmaceuticals. In collaboration with DILI genomics consortium at US, EU and UK, we’ve found +20,000 genetic make up (variants) defines potential risk of developing Drug induced liver injury thru amplifying cellular stress signal cascades that were investigated by human cell, organoid and patient datasets. (more…)
Allergies, Author Interviews, Dermatology, Pediatrics / 25.07.2020

MedicalResearch.com Interview with: Catherine M. Ludwig is a 4th year medical student at the University of Illinois Chicago College of Medicine. Her interests in dermatology include inflammatory and genetic conditions, especially within pediatric dermatology.     Alyssa M. Thompson is currently a 2nd year medical student at the UA-COM Tucson. She graduated from the University of Arizona, Summa Cum Laude in 2018 as the athletic department's Valedictorian with a degree in Physiology and an Entrepreneurship certificate. Her passion for research and dermatology stems from her innovative and integrative mindset with specific interest in inflammatory skin disease.     MedicalResearch.com: What is the background for this study? Response: Eczema is very common in children. Prescription medications are important for managing eczema flares, but a lot of the work in treating eczema is preventative, done by consistently moisturizing the skin at home with drug store products. Allergic contact dermatitis occurs more commonly in people with eczema. A previous study was done in characterizing the allergenic potential of drug-store moisturizers and found that 88% of moisturizers contain at least one common allergen. Many moisturizers are marketed specifically to eczema, but the allergen content of these products are unknown. (more…)
Allergies, Author Interviews, Pediatrics / 24.07.2020

MedicalResearch.com Interview with: Kirsten P Perrett MD PhD Group Leader/Clinician Scientist Fellow Population Allergy Research Group and Melbourne Children's Trial Centre Murdoch Children's Research Institute   Rachel L Peters PhD Murdoch Children’s Research Institute Department of Paediatrics The University of Melbourne Parkville, Australia MedicalResearch.com: What is the background for this study? cashews-wikipedia-image Response: The prevalence of food allergy has increased over the last 1-2 decades. Historically, parents were advised to withhold the introduction of allergenic foods, such as peanut or egg, until after the infant was 1-3 years of age in the hope that it would prevent food allergy. However, recent evidence has shown that introducing peanut and egg in the first year of life, reduces the risk of allergy to that food. This has led to a paradigm shift in infant feeding advice from active avoidance to timely introduction. However, there has not been any research advising on the timing of tree nuts, a common cause of food allergy, MedicalResearch.com: What are the main findings? Response: Our study of nearly 3000 children in the population-based HealthNuts study in Australia, found that only 5% had eaten cashew by age 12 months. Interestingly, no child who consumed cashew by age 12 months, developed cashew allergy at age 6 years; conversely 3.6% of those who had not consumed cashew by age 12 months did develop cashew allergy at age 6 years. Our findings suggest that introducing cashew in the first year of life may reduce the risk of cashew allergy. (more…)
Allergies, Author Interviews, Dermatology / 22.07.2020

MedicalResearch.com Interview with: Emma Guttman-Yassky, MD, PhD Professor of Dermatology and Immunology Vice Chair of the Department of Dermatology Icahn School of Medicine MedicalResearch.com: What is the background for this study? What is the importance of differentiating these two skin conditions?   Response: The background is that up to now skin biopsies were considered the gold standard for obtaining skin biomarkers of atopic dermatitis/AD and psoriasis that are linked to disease activity in skin and for obtaining the cutaneous gene and protein expression fingerprint of each individual disease. Biopsies are also used in clinical trials to obtain the skin phenotype. However biopsies are invasive, painful and scarring. Thus we need less invasive means to profile diseases and obtain biomarkers. Tape strips is a minimally invasive approach to sample and study the skin. However, prior studies using tape strips could not fully capture the phenotype of the diseases and also sampling the recovery rate was less than optimal, not allowing this approach to be widely used. Psoriasis and AD are the most common inflammatory skin diseases, but these diseases are treated very differently and in some cases are very difficult to differentiate between them clinically and even in biopsies.  (more…)
Allergies, Author Interviews / 20.07.2020

MedicalResearch.com Interview with: Dr. Todd Green Vice President of Clinical Development and Medical Affairs https://www.dbv-technologies.com MedicalResearch.com: What is the background for this study? Response: The PEOPLE study is an open-label extension of the Phase III PEPITES trial designed to evaluate the long-term safety, tolerability and efficacy of Viaskin Peanut 250 μg (DBV712). Participants who completed the 12-month study period of PEPITES were eligible to enroll in PEOPLE, which evaluates the eliciting dose (ED) after three years (Month 36) of active treatment using a double-blind, placebo-controlled food challenge (DBPCFC).  (more…)
Allergies, Author Interviews, JAMA, OBGYNE / 05.06.2020

MedicalResearch.com Interview with: Niklas Andersson MS Department of Epidemiology Research Statens Serum Institut Copenhagen S, Denmark MedicalResearch.com: What is the background for this study? What are the main findings? Response: Second-generation antihistamines are among the most commonly prescribed drug classes during pregnancy. Fexofenadine is a widely used antihistamine but given the limited fetal safety on the use of antihistamines during pregnancy in general, current clinical guidelines only recommend the use cetirizine and loratadine during pregnancy when needed due to a larger body of fetal safety data for these antihistamines. (more…)